HF & Diabetes: SGLT2 inhibition a paradigm shift?
This lecture was part of a CME accredited symposium: SGLT2 Inhibition, Diabetes and CVD: Where does this fit in CV risk management? held at ESC 2016 in Rome
Video navigation menu
- Multiple hypotheses on prevention of heart failure and reduction of mortality by SGLT-2 inhibitors 01:31
- Direct or indirect effect on myocardium by SGLT-2 inhibitors 02:55
- Lack of effect on myocardial infarction and absence of evidence for antiarrhythmic effect by SGLT-2 inhibitors 04:10
- Blood pressure-lowering effect of SGLT-2 inhibitors 05:13
- Renal effect of SGLT-2 inhibitors 11:40
- Heart failure and mortality 12:54
- Can we treat established heart failure with SGLT-2 inhibitors? 16:36
Educational objectives of this symposium were to:
- Summarise the epidemiology and pathophysiology of patients at increased cardiovascular risk and diabetes
- Identify key components of renal glucose handling and the contribution of the kidney to glucose homeostasis
- Describe the effect of multiple interventions that currently are deployed for T2D on cardiovascular safety and the currently unmet need on impacting cardiovascular outcomes
- Explain, based on scientific evidence, the effects that SGLT2 inhibiting agents may have on cardiometabolic markers, including lipids, weight gain, risk of hypoglycemia, HbA1c, glucose levels, related markers and cardiovascular outcomes
- Discuss current and future strategies for practical management and interventions to prevent cardiovascular events in multi-risk patients
This symposium was accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credit(s).
Professor John McMurray: Professor of Medical Cardiology & Deputy - Director Institute of Cardiovascular & Medical Sciences - University of Glasgow, United Kingdom
Supported by an unrestricted educational grant from Boehringer Ingelheim/Lilly.